iBio, Inc. (IBIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
IBIO Chart
iBio Reports Fiscal Third Quarter 2025 Financial Results
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.
iBio Raises $6.2 Million Through Warrant Inducement Transaction
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days
iBio, Inc. Dividends
iBio, Inc. Earnings
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 7 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 25 Sep 2024 Date | | - Cons. EPS | - EPS |
| 14 May 2024 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 7 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 25 Sep 2024 Date | | - Cons. EPS | - EPS |
| 14 May 2024 Date | | - Cons. EPS | - EPS |
iBio, Inc. (IBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iBio, Inc. ever had a stock split?
iBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Martin B. Brenner D.V.M., Ph.D. CEO | NASDAQ (CM) Exchange | 451033203 Cusip |
| US Country | 16 Employees | - Last Dividend | 29 Nov 2023 Last Split | - IPO Date |
Overview
iBio, Inc. is positioned at the forefront of biotechnological innovation by leveraging artificial intelligence (AI) to pioneer the development of next-generation biopharmaceuticals. The company's specialization in computational biology and 3D modeling of subdominant and conformational epitopes paves the way for the discovery of novel antibody treatments, particularly focusing on challenging cancer targets and other diseases. Since its incorporation in 2008 and based in San Diego, California, iBio, Inc. endeavors to transition vaccines and therapeutics from preclinical stages into groundbreaking medical solutions. With EngageTx™ and ShieldTx™ technologies under its belt, iBio is striving to redefine therapeutic and vaccine discovery and delivery, promising a future where treatment is not only more effective but also safer for patients.
Products and Services
- EngageTx™ Technology
- ShieldTx™ Technology
At the heart of iBio’s innovation, the EngageTx™ technology stands out for its focus on bi-specific molecules. This platform distinguishes itself by generating multiple hits, hence creating a vast sequence diversity. It is particularly notable for promoting Human-Cyno cross-reactivity, which is crucial for ensuring the efficacy of treatments across different species during the preclinical testing phase. Furthermore, EngageTx™ is designed to mitigate cytokine release, a common concern in the development of therapies, thus enhancing the safety profile of prospective treatments.
ShieldTx™ emerges as iBio's answer to the critical challenge of targeted antibody delivery. This patent-pending antibody masking technology is engineered with precision to ensure that therapeutic antibodies reach only diseased tissues, sparing the healthy ones from potential damage. This revolutionary approach not only maximizes the efficacy of treatments but also significantly minimizes side effects, offering a beacon of hope for patients with conditions that require highly targeted therapeutic interventions.
Contact Information
